SanBio Company Limited (TYO:4592)

Market Cap	99.27B -40.5%
Revenue (ttm)	n/a
Net Income	-3.84B
EPS	-52.55
Shares Out	78.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,634,900
Open	1,242.00
Previous Close	1,272.00
Day's Range	1,173.00 - 1,283.00
52-Week Range	1,177.00 - 3,990.00
Beta	0.31
Analysts	Hold
Price Target	2,100.00 (+66.67%)
Earnings Date	Jun 15, 2026

About SanBio Company

SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company’s research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction injury, chronic cerebral hemorrhage, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 33
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4592

Analyst Summary

According to 5 analysts, the average rating for 4592 stock is "Hold." The 12-month stock price target is ¥2,100, which is an increase of 66.67% from the latest price.

Price Target

¥2,100

(66.67% upside)

Analyst Consensus: Hold